Characterization of in vitro pharmacokinetic properties of hoodigogenin a from hoodia gordonii

Planta Medica

Volumn 76, Issue 1, 2010, Pages 62-69

  Madgula, Vamsi Lakshmi Mohan ^a   Avula, Bharathi ^a   Pawar, Rahul S ^a   Shukla, Yatin J ^a   Khan, Ikhlas A ^a,b   Walker, Larry A ^a,b   Khan, Shabana I ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Asclepiadaceae; CYP inhibition; Hoodia gordonii; Hoodigogenin A; Intestinal and blood brain barrier transport; Metabolic stability

Indexed keywords

AGLYCONE; CYTOCHROME P450 3A4; HOODIGOGENIN A; OXYPREGNANE STEROIDAL GLYCOSIDE; PLANT EXTRACT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ASCLEPIADACEAE; BLOOD BRAIN BARRIER; CELL STRAIN; CELL STRAIN CACO 2; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STABILITY; DRUG STRUCTURE; HOODIA GORDONII; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; INTESTINE FLUID; LIVER MICROSOME; MEDICINAL PLANT; NONHUMAN; STOMACH JUICE;

APOCYNACEAE; BLOOD PROTEINS; CACO-2 CELLS; CYTOCHROME P-450 CYP3A; GASTRIC JUICE; HERB-DRUG INTERACTIONS; HUMANS; INTESTINAL ABSORPTION; INTESTINES; LIVER; MICROSOMES; MOLECULAR STRUCTURE; PLANT EXTRACTS; PREGNANEDIOL;

APOCYNACEAE; HOODIA GORDONII;

EID: 74549168370     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0029-1185949     Document Type: Article

References (41)

1. South African National Biodiversity Institute. Plants of Southern Africa. Available at www.plantzafrica.com. Accessed April 4, 2009[nl]
2. Rubin D I., Cawthorne M A., Bindra J S. Extracts, compounds and pharmaceutical compositions having anti-diabetic activity and their uses. US Patent 7416744B2 2008
3. Rubin D I., Cawthorne M A., Bindra J S. Extracts, compounds and pharmaceutical compositions having anti-diabetic activity and their use. Euro Patent 1166792 2002
4. Pawar R S., Shukla Y J., Khan S I., Avula B, Khan I A. New oxypregnane glycosides from appetite suppressant herbal supplement Hoodia gordonii. Steroids 2007 72 524-534
5. van Heerden F R., Marthinus Horak R, Maharaj V J., Vleggaar R, Senabe J V., Gunning P J. An appetite suppressant from Hoodia species. Phytochemistry 2007 68 2545-2553
6. MacLean D B., Luo L G. Increased ATP content/production in the hypothalamus may be a signal for energy-sensing of satiety: studies of the anorectic mechanism of a plant steroidal glycoside. Brain Res 2004 1020 1-11
7. Madgula V L., Avula B, Pawar R S., Shukla Y J., Khan I A., Walker L A., Khan S I. In vitro metabolic stability and intestinal transport of P57AS3 (P57) from Hoodia gordonii and its interaction with drug metabolizing enzymes. Planta Med 2008 74 1269-1275
8. Gee J M., DuPont M S., Day A J., Plumb G W., Williamson G, Johnson I T. Intestinal transport of quercetin glycosides in rats involves both deglycosylation and interaction with the hexose transport pathway. J Nutr 2000 130 2765-2771
9. Day A J., Canada F J., Diaz J C., Kroon P A., McLauchlan R, Faulds C B., Plumb G W., Morgan M R., Williamson G. Dietary flavonoid and isoflavone glycosides are hydrolysed by the lactase site of lactase phlorizin hydrolase. FEBS Lett 2000 468 166-170
10. Day A J., DuPont M S., Ridley S, Rhodes M, Rhodes M J., Morgan M R., Williamson G. Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver beta-glucosidase activity. FEBS Lett 1998 436 71-75
11. Andlauer W, Kolb J, Furst P. Isoflavones from tofu are absorbed and metabolized in the isolated rat small intestine. J Nutr 2000 130 3021-3027
12. Liu Y, Hu M. Absorption and metabolism of flavonoids in the caco-2 cell culture model and a perused rat intestinal model. Drug Metab Dispos 2002 30 370-377
13. Walgren R A., Karnaky Jr K J., Lindenmayer G E., Walle T. Efflux of dietary flavonoid quercetin 4-beta-glucoside across human intestinal Caco-2 cell monolayers by apical multidrug resistance-associated protein-2. J Pharmacol Exp Ther 2000 294 830-836
14. Brown J E., Khodr H, Hider R C., Rice-Evans C A. Structural dependence of flavonoid interactions with Cu2+ ions: implications for their antioxidant properties. Biochem J 1998 330 (Pt 3) 1173-1178
15. Kay C D. Aspects of anthocyanin absorption, metabolism and pharmacokinetics in humans. Nutr Res Rev 2006 19 137-146
16. Gumbleton M, Audus K L. Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier. J Pharm Sci 2001 90 1681-1698
17. Wang Q, Rager J D., Weinstein K, Kardos P S., Dobson G L., Li J, Hidalgo I J. Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. Int J Pharm 2005 288 349-359
18. The United States Pharmacopeia XXXI/The National Formulary 26 USP/NF. Solutions/Test solutions. Rockville The United States Pharmacopeial Convention 2008 817
19. Asafu-Adjaye E B., Faustino P J., Tawakkul M A., Anderson L W., Yu L X., Kwon H, Volpe D A. Validation and application of a stability-indicating HPLC method for the in vitro determination of gastric and intestinal stability of venlafaxine. J Pharm Biomed Anal 2007 43 1854-1859
20. Madgula V L., Avula B, Reddy V L. N., Khan I A., Khan S I. Transport of decursin and decursinol angelate across Caco-2 and MDR-MDCK cell monolayers: in vitro models for intestinal and blood-brain barrier permeability. Planta Med 2007 73 330-335
21. Madgula V L., Avula B, Choi Y W., Pullela S V., Khan I A., Walker L A., Khan S I. Transport of Schisandra chinensis extract and its biologically-active constituents across Caco-2 cell monolayers an in-vitro model of intestinal transport. J Pharm Pharmacol 2008 60 363-370
22. Obach R S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 1999 27 1350-1359
23. Crespi C L., Miller V P., Penman B W. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem 1997 248 188-190
24. Harvard Bioscience Inc. Guide to equilibrium dialysis. Southborough The Nest Group, Inc. 2008
25. Food and Drug Administration. Guidance for industry, waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms containing certain active moieties/active ingredients based on biopharmaceutical classification system. Rockville CDER, Department of Health and Human Services 2000
26. Gres M C., Julian B, Bourrie M, Meunier V, Roques C, Berger M, Boulenc X, Berger Y, Fabre G. Correlation between oral drug absorption in humans, and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: comparison with the parental Caco-2 cell line. Pharm Res 1998 15 726-733
27. Stewart B H., Chan O H., Lu R H., Reyner E L., Schmid H L., Hamilton H W., Steinbaugh B A., Taylor M D. Comparison of intestinal permeabilities determined in multiple in vitro and in situ models: relationship to absorption in humans. Pharm Res 1995 12 693-699
28. Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 1991 175 880-885
29. Garberg P, Ball M, Borg N, Cecchelli R, Fenart L, Hurst R D., Lindmark T, Mabondzo A, Nilsson J E., Raub T J., Stanimirovic D, Terasaki T, Oberg J O., Osterberg T. In vitro models for the blood-brain barrier. Toxicol In Vitro 2005 19 299-334
30. Camenisch G, Alsenz J, van de Waterbeemd H, Folkers G. Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. Eur J Pharm Sci 1998 6 317-324
31. Obach R S., Baxter J G., Liston T E., Silber B M., Jones B C., MacIntyre F, Rance D J., Wastall P. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 1997 283 46-58
32. Butterweck V, Derendorf H, Gaus W, Nahrstedt A, Schulz V, Unger M. Pharmacokinetic herb-drug interactions: are preventive screenings necessary and appropriate? Planta Med 2004 70 784-791
33. CDER Department of Health and Human Services CBER FDA. Drug interaction studies: study design data analysis, and implications for dosing and labelling. Rockville Food and Drug Administration 2004
34. Liu Y, Yang L. Early metabolism evaluation making traditional Chinese medicine effective and safe therapeutics. J Zhejiang Univ Sci B 2006 7 99-106
35. Barone G W., Gurley B J., Ketel B L., Lightfoot M L., Abul-Ezz S R. Drug interaction between St. John's wort and cyclosporine. Ann Pharmacother 2000 34 1013-1016
36. Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract. N Engl J Med 1997 336 1108
37. Usia T, Iwata H, Hiratsuka A, Watabe T, Kadota S, Tezuka Y. CYP3A4 and CYP2D6 inhibitory activities of Indonesian medicinal plants. Phytomedicine 2006 13 67-73
38. Huang J D., Oie S. Effect of altered disopyramide binding on its pharmacologic response in rabbits. J Pharmacol Exp Ther 1982 223 469-471
39. Qin M, Nilsson M, Oie S. Decreased elimination of drug in the presence of alpha-1-acid glycoprotein is related to a reduced hepatocyte uptake. J Pharmacol Exp Ther 1994 269 1176-1181
40. Shand D G., Cotham R H., Wilkinson G R. Perfusion-limited of plasma drug binding on hepatic drug extraction. Life Sci 1976 19 125-130
41. Jansen J A. Influence of plasma protein binding kinetics on hepatic clearance assessed from a tube model and a well-stirred model. J Pharmacokinet Biopharm 1981 9 15-26